Status:
UNKNOWN
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Lead Sponsor:
Ministry of Health, Saudi Arabia
Conditions:
Coronavirus
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II tran...
Eligibility Criteria
Inclusion
- Positive RT-PCR) assay for SARS-CoV-2
- Age \>18 years
- Hospitalized
- Able to give informed consent
Exclusion
- Known allergy to AAT
- imminent death within next 24 hours
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04385836
Start Date
June 1 2020
End Date
September 1 2020
Last Update
May 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ministry of Health
Mecca, Saudi Arabia